Table 1 Antimicrobial susceptibility of causative microorganisms of breakthrough bloodstream infection.
Pathogen and antibiotic | No. of susceptible isolates /total no. of isolates (%) |
|---|---|
Klebsiella pneumoniae (n = 28) | |
Amikacin | 20/28 (71.4) |
Aztreonam | 7/20 (35) |
Cefepime | 5/28 (17.9) |
Cefotaxime | 5/28 (17.9) |
Ciprofloxacin | 6/28 (21.4) |
Meropenem | 19/28 (67.9) |
Piperacillin/tazobactam | 15/28 (53.6) |
Tetracycline | 1/28 (3.6) |
Tigecycline | 8/16 (50) |
Pseudomonas aeruginosa (n = 20) | |
Amikacin | 18/20 (90) |
Cefepime | 14/20 (70) |
Ceftazidime | 15/20 (75) |
Ciprofloxacin | 14/20 (70) |
Meropenem | 13/20 (65) |
Piperacillin/tazobactam | 14/20 (70) |
Acinetobacter baumannii (n = 18) | |
Amikacin | 3/18 (16.7) |
Cefepime | 2/18 (11.1) |
Ceftazidime | 1/18 (5.6) |
Levofloxacin | 1/18 (5.6) |
Meropenem | 1/18 (5.6) |
Piperacillin/tazobactam | 1/7 (14.3) |
Tetracycline | 0/10 (0) |
Tigecycline | 10/13 (76.9) |
Candida species (n = 21) | |
Amphotericin B | 21/21 (100) |
Fluconazole | 15/21 (71.4) |
Voriconazole | 20/21 (95.2) |
